165 related articles for article (PubMed ID: 38690285)
1. Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.
Liu J; Hu S; Jiang H; Cui Y
Front Immunol; 2024; 15():1369972. PubMed ID: 38690285
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide-associated hypermutation in gliomas.
Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
[TBL] [Abstract][Full Text] [Related]
4. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Mathur R; Zhang Y; Grimmer MR; Hong C; Zhang M; Bollam S; Petrecca K; Clarke J; Berger MS; Phillips JJ; Oberheim-Bush NA; Molinaro AM; Chang SM; Costello JF
Neuro Oncol; 2020 Nov; 22(11):1580-1590. PubMed ID: 32166314
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
9. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M; Li YY; Boynton AN; Spurr LF; Iorgulescu JB; Bohrson CL; Cortes-Ciriano I; Birzu C; Geduldig JE; Pelton K; Lim-Fat MJ; Pal S; Ferrer-Luna R; Ramkissoon SH; Dubois F; Bellamy C; Currimjee N; Bonardi J; Qian K; Ho P; Malinowski S; Taquet L; Jones RE; Shetty A; Chow KH; Sharaf R; Pavlick D; Albacker LA; Younan N; Baldini C; Verreault M; Giry M; Guillerm E; Ammari S; Beuvon F; Mokhtari K; Alentorn A; Dehais C; Houillier C; Laigle-Donadey F; Psimaras D; Lee EQ; Nayak L; McFaline-Figueroa JR; Carpentier A; Cornu P; Capelle L; Mathon B; Barnholtz-Sloan JS; Chakravarti A; Bi WL; Chiocca EA; Fehnel KP; Alexandrescu S; Chi SN; Haas-Kogan D; Batchelor TT; Frampton GM; Alexander BM; Huang RY; Ligon AH; Coulet F; Delattre JY; Hoang-Xuan K; Meredith DM; Santagata S; Duval A; Sanson M; Cherniack AD; Wen PY; Reardon DA; Marabelle A; Park PJ; Idbaih A; Beroukhim R; Bandopadhayay P; Bielle F; Ligon KL
Nature; 2020 Apr; 580(7804):517-523. PubMed ID: 32322066
[TBL] [Abstract][Full Text] [Related]
11. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
[TBL] [Abstract][Full Text] [Related]
12. Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
Schaff LR; Kushnirsky M; Lin AL; Nandakumar S; Grommes C; Miller AM; Gavrilovic IT; Nolan C; Pentsova E; Mellinghoff IK; Kaley TJ
Neurology; 2022 Oct; 99(17):750-755. PubMed ID: 35948444
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
14. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
[TBL] [Abstract][Full Text] [Related]
15. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
17. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
18. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P; Kurscheid S; Delorenzi M; Gorlia T; van den Bent MJ; Hoang-Xuan K; Vauléon É; Gijtenbeek A; Enting R; Thiessen B; Chinot O; Dhermain F; Brandes AA; Reijneveld JC; Marosi C; Taphoorn MJB; Wick W; von Deimling A; French P; Stupp R; Baumert BG; Hegi ME
Acta Neuropathol; 2018 Apr; 135(4):601-615. PubMed ID: 29368212
[TBL] [Abstract][Full Text] [Related]
19. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
20. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Parlato C; Barbarisi M; Moraci M; Moraci A
Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
